neoantigen-loaded autologous dendritic cells

Neoantigen-loaded autologous dendritic cells are a personalized cancer immunotherapy designed to elicit a targeted immune response against a patient's unique tumor mutations. The therapeutic process involves isolating dendritic cells (DCs) from the patient's blood and maturing them ex vivo. These DCs are then pulsed or loaded with synthetic peptides representing tumor-specific neoantigens, which are identified through genomic sequencing and bioinformatic analysis of the patient's tumor tissue. Once re-administered to the patient, these matured, neoantigen-presenting DCs migrate to lymph nodes where they prime and activate neoantigen-specific T cells. This approach aims to generate a robust, mutation-specific anti-tumor response while minimizing off-target effects on healthy tissues, as neoantigens are exclusively expressed by malignant cells.

Other names

neoantigen-loaded dendritic cell therapyautologous dendritic cell vaccination loaded with patient-specific neoantigen peptides